Vir Pharma's clinical studies contribute to the development of a proprietary cannabis-based prescription drug for
"This is a significant announcement for Sundial and our Heal (medical) business as it will lead to our first global exports and entry into Australian markets," said Brian Harriman, Chief Operating Officer of Sundial. "We're excited to be working with a leading company such as Vir Pharma to provide Australian patients with high-quality, cannabis-based therapies."
Pursuant to the Agreement, Sundial will work with Vir Pharma to develop a cannabis oil blend focused on chronic pain, which will be marketed under Vir Pharma's brand name, Virabis.
"At Vir Pharma, we believe that full spectrum cannabis medicines could be a useful second line therapy to reduce opiate consumption and enhance the lives of people living in chronic pain," said
The relationship between Sundial and Vir Pharma will enable shared learnings and capabilities, allowing both parties to leverage each other's expertise and opening the door to developing innovative medical cannabis therapies moving forward.
Sundial expects to export the first shipment of cannabis oil to Vir Pharma before the end of
About
Sundial proudly crafts pioneering cannabis brands to Heal, Help and Play:
- Heal - cannabis products used as prescription medicine
- Help - cannabis products that strive to promote health and wellness through CBD
- Play - cannabis products to enhance social, spiritual and recreational occasions
Sundial has facilities in
In
In the
We employ over 1,000 employees globally, full-time and seasonal, bringing economic benefits to the local communities in which we operate.
For more information about Sundial, visit www.sndlgroup.com and follow us on Twitter @SundialCannabis, Instagram @SundialCannabis, LinkedIn @SundialCannabis and Facebook @SundialCommunity.
About
Vir Pharma is an Australian owned licenced importer and manufacturer of medical cannabis. We've set out to cultivate natural, full spectrum medicines that include the whole plant to enhance the lives of people living in chronic pain.
Our board consists of experienced pharmaceutical and nutraceutical executives that have worked and sold high quality pharma grade products throughout the world.
We focus on genetics grown under Australian conditions through tissue culture propagation, a method which delivers a consistent, natural product, free from pests and chemical dependencies.
Forward-Looking Information Cautionary Statement
This news release includes statements containing certain "forward-looking information" within the meaning of applicable securities law ("forward-looking statements"). Forward-looking statements are frequently characterized by words such as "plan", "continue", "expect", "project", "intend", "believe", "anticipate", "estimate", "may", "will", "potential", "proposed" and other similar words, or statements that certain events or conditions "may" or "will" occur. These statements are only predictions. Various assumptions were used in drawing the conclusions or making the projections contained in the forward-looking statements throughout this news release. Forward-looking statements are based on the opinions and estimates of management at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable law.
SOURCE
© Canada Newswire, source